Practical NeurologyBuntanetap Treatment for Parkinson Disease Linked to Improvements in Motor, Non-Motor, and Cognitive Functions

Potential Neuroprotective Effects of Buntanetap in Parkinson’s Disease and Beyond

A phase 3 clinical trial evaluated the efficacy of buntanetap, an oral molecule, in treating early Parkinson’s disease (PD). The study found improvements in motor, non-motor, and cognitive functions among participants treated with buntanetap compared to placebo.

Study Design:

• Phase 3 prospective, double-blind, placebo-controlled clinical trial
• 450 participants aged 40-85 with idiopathic PD
• MMSE scores between 20 and 30
• 6-month treatment period
• Dosages: placebo, 10 mg buntanetap, or 20 mg buntanetap daily
• Primary outcomes: change in MDS-UPDRS Part II score, safety, and tolerability
• Secondary endpoints: MDS-UPDRS Parts III, II+III, and Total scores

Key Findings:

• Buntanetap-treated participants maintained baseline cognition levels
• 20 mg buntanetap improved cognition in participants with mild dementia
• Significant improvements in MDS-UPDRS scores for participants diagnosed >3 years ago
• Participants with postural instability and gait difficulty showed better response to treatment
• Buntanetap was found to be safe and well-tolerated

HCN Medical Memo
Although these results are promising, longer-term studies are needed to confirm the observed symptomatic improvements and explore the potential disease-modifying properties of buntanetap. Clinicians should monitor ongoing research to assess the future role of buntanetap in managing Parkinson’s disease and potentially other neurodegenerative disorders.

More on Parkinson’s Disease